Format

Send to

Choose Destination
Bioorg Med Chem. 2018 Jun 1;26(10):2842-2849. doi: 10.1016/j.bmc.2017.10.021. Epub 2017 Oct 19.

Personalized neoantigen vaccines: A new approach to cancer immunotherapy.

Author information

1
Neon Therapeutics, Cambridge, MA 02139, USA.
2
Neon Therapeutics, Cambridge, MA 02139, USA. Electronic address: jdong@neontherapeutics.com.

Abstract

Neoantigens arise from somatic mutations that differ from wild-type antigens and are specific to each individual patient, which provide tumor specific targets for developing personalized cancer vaccines. Decades of work has increasingly shown the potential of targeting neoantigens to generate effective clinical responses. Current clinical trials using neoantigen targeting cancer vaccines, including in combination with checkpoint blockade monoclonal antibodies, have demonstrated potent T-cell responses against those neoantigens accompanied by antitumor effects in patients. Personalized neoantigen vaccines represent a potential new class of cancer immunotherapy.

KEYWORDS:

Neoantigen; Peptide; Personalized; Vaccine

PMID:
29111369
DOI:
10.1016/j.bmc.2017.10.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center